Peter Crow, MD
Hematology & Oncology · Hooksett, NHNPI 1740233816
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $150 of the $223 with a category attached, or 67.2%. Janssen Scientific Affairs, LLC accounts for 67.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $150, more than ten times the $15 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in NH, where the typical reported total is $223.
Across 5 payments — averaging $44.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$150
- CSL Behring$30
- Novocure Inc.$16
- Pfizer$15
- Karyopharm Therapeutics Inc.$12
What the payments were for
- Consulting fees$15067%
- Food & beverage$167%
- Education$5726%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 1 | $150 |
| CSL Behring | 1 | $30 |
| Novocure Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TALVEY$150
How this compares
$223 in reported general payments places this provider in the 50th percentile of 61 hematology & oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 15 | $16,238 |
| Anastrozole | 77 | $1,736 |
| Tamoxifen Citrate | 12 | $458 |
| Letrozole | 28 | $411 |
| Acyclovir | 15 | $237 |
| Olanzapine | 19 | $212 |
| Dexamethasone | 17 | $176 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $167 |
| Prednisone | 23 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $150 | $16,23815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 61 hematology & oncology providers in New Hampshire.
Other hematology & oncology in Hooksett
- Danny SimsHooksett$43
- Frederick LansiganLebanon$23K
- Parth ShahLebanon$18K
- Nancy ChunNashua$7K
- Amy BessnowDover$6K
- Konstantin DragnevLebanon$5K
- Keisuke ShiraiLebanon$5K
- Eric LubinerNorth Conway$3K
- David ReismanManchester$2K
- Ivy Riano MonsalveLebanon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.